Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06516042

Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia

Effectiveness, Feasibility, and Acceptability of Targeted Antimalarial Interventions for Seasonal Migrant Populations in Metema District, Amhara Region, Ethiopia

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
10,350 (estimated)
Sponsor
PATH · Academic / Other
Sex
All
Age
14 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to assess the effectiveness, feasibility, and acceptability of targeted drug administration for seasonal migrant populations in Metema District, Amhara Region, Ethiopia

Detailed description

A cluster randomized controlled trial will be used to evaluate the effectiveness, feasibility, and acceptability of targeted antimalarial drug administration (TDA) for seasonal migrant farmworkers in the Delello farm sites in Metema district, Amhara Region. Individual farm sites will be randomized 1:1:1 to either of two intervention options or control, where all farmworkers at intervention sites will receive either two or three rounds of dihydro artemisinin piperaquine over the primary farming season. All study farm-sites will receive enhanced case management conducted by mobile health teams throughout the study period. Cross-sectional surveys will be conducted in all arms at baseline and 4 to 6 weeks following the third round of TDA to assess the effectiveness of the intervention for reducing parasite prevalence.

Conditions

Interventions

TypeNameDescription
DRUGDihydroartemisinin-piperaquineParticipants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.

Timeline

Start date
2024-08-21
Primary completion
2025-01-24
Completion
2025-07-01
First posted
2024-07-23
Last updated
2025-05-06

Locations

1 site across 1 country: Ethiopia

Source: ClinicalTrials.gov record NCT06516042. Inclusion in this directory is not an endorsement.